IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3839
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$5M
Kevin S. Boyle
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$TCRT Alaunos Therapeutics, Inc. | 38 | 21 | 12 | 62 | - | - | -157.3% | -118.4% | - | -54600.0% | -53650.0% | -100.0% | 0.0% | 33.0x | $5M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Alaunos Therapeutics, Inc. (TCRT) receives a "Avoid" rating with a composite score of 37.5/100. It ranks #3839 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Kevin S. Boyle
Chief Executive Officer
Labor Force
40
21
25
40
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for TCRT
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for TCRT.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy -157.3% (sector -2.5%)
GM N/A vs sector 43%, OM -54600% vs sector 1%
Capital turnover N/A
Rev growth -100%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Alaunos Therapeutics, Inc. with an Avoid rating, assigning a composite score of 37.5/100 and 1 out of 5 stars. Ranked #3839 of 7,333 stocks, TCRT falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Alaunos Therapeutics, Inc. registers a weak quality score of just 21/100, indicating significant profitability challenges. The company reports a return on equity of -157.3% (sector avg: -2.5%), net margins of -53650.0% (sector avg: -0.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
TCRT registers a value score of just 12/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 2.17x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Alaunos Therapeutics, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -100.0% vs. a sector average of 5.9% and a return on assets of -118.4% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
TCRT demonstrates moderate momentum with a score of 62/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -100.0% year-over-year, while a beta of 0.46 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
TCRT's stability score of 40/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.46 and a debt-to-equity ratio of 33.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
TCRT carries a short interest score of 69/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 33.00x), micro-cap liquidity risk. At $5M market cap (micro-cap), Alaunos Therapeutics, Inc. offers reasonable institutional liquidity.
Alaunos Therapeutics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3839 of 7,333 overall (48th percentile). Key comparisons include ROE of -157.3% trailing the -2.5% sector median and operating margins of -54600.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While TCRT currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (12) would have the largest impact on the composite score.
ROE 6244% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 4232658% BELOW SECTOR MEDIAN
Debt/Equity 16400% ABOVE SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Alaunos Therapeutics, Inc. (TCRT) as Avoid with a composite score of 37.5/100 at a current price of $2.81. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (62th percentile) and stability (40th percentile), which together account for the majority of the composite score. Offsetting weakness in value (12th percentile) and quality (21th percentile) tempers our overall conviction. We assign a No Moat rating (25/100), High uncertainty, and Poor capital allocation.
Key items to watch: whether strong momentum is fundamentally supported by revenue trends; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is narrowing, which raises the risk of a future downgrade if the trend persists.
Alaunos Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 37.5/100 places it at rank #3839 in our full 7,333-stock universe. At $5M in market capitalization, Alaunos Therapeutics, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Despite positive momentum (62th percentile), revenue contraction of -100% creates a divergence between price action and fundamental trajectory. This divergence suggests either that the market is looking through near-term weakness or that technical factors are temporarily inflating the stock. Investors should assess whether the revenue decline reflects cyclical weakness or structural challenges.
Available margin data shows operating margins of -54600%. Incomplete margin data limits our ability to fully assess the cost structure and margin trajectory, though the available metrics provide a partial view of operating efficiency.
At a current price of $2.81, Alaunos Therapeutics, Inc. is trading at a premium to fundamental value. Our value factor score of 12/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 2.2x, P/S of 3035.3x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 37.5/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -100% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -53650.0% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Below-average quality (21th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a High uncertainty rating to Alaunos Therapeutics, Inc.. Key risk factors include current negative profitability (net margin -53650.0%), below-average price stability (40th percentile), weak quality scores (21th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -53650.0%); below-average price stability (40th percentile); weak quality scores (21th percentile); low beta of 0.46 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 40th percentile and quality factor at the 21th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Alaunos Therapeutics, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-157.3%), negative profitability, weak asset returns (ROA -118.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Alaunos Therapeutics, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Alaunos Therapeutics, Inc. receives a Avoid rating with a composite score of 37.5/100 (rank #3839 of 7,333). Our quantitative framework assigns a No Moat (25/100, trend: narrowing), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 32/100.
Our analysis does not support a constructive view on Alaunos Therapeutics, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Alaunos Therapeutics, Inc. a meaningful economic moat, scoring 25/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 9.8/20.
The strongest moat sources are growth durability (9.8/20) and margin superiority (9/20). Rev growth -100%, 10yr history. GM N/A vs sector 43%, OM -54600% vs sector 1%. These pillars form the core of Alaunos Therapeutics, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (0/20). ROE proxy -157.3% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Narrowing. ROIC has declined at ~288.0pp per year, and operating margins show fundamental deterioration. Investors should monitor these indicators closely — a sustained narrowing trend often precedes material downgrades in our moat assessment.
Key profit drivers include declining revenues (-100%) that pressure the earnings outlook. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 21th percentile.
The margin profile shows operating margins of -54600%, net margins of -53650.0%. Return metrics include ROE of -157.3% and ROA of -118.4%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -157.3% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 33%, revenue growth of -100%. The sector median D/E is 0%, putting Alaunos Therapeutics, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. C.H. Robinson Worldwide posted adjusted earnings of 50 cents per share, missing market estimates if 81 cents per share. The company’s quarterly sales came in at $4.20 billion versus estimates of $4.34 billion. C.H. Robinson Worldwide shares dipped 12.6% to $73.49 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ: MINM) shares climbed 57.3% to $6.45. David E. Lazar recently disclosed a 51% active stake in Minim. Clearmind Medicine Inc. (NASDAQ: CMND) jumped 51% to $2.17. Clearmind Medicine announced long-term licensing agreement with BIRAD. NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) climbed 52.9% to $5.00. NeuroBo Pharmaceuticals announced FDA clearance of IND for Phase 1 clinical trial of DA-1726 for the treatment of obesity. FibroBiologics, Inc. (NASDAQ: FBLG) shares climbed 47.4% to $42.90. FibroBiologics announced direct listing on the NASDAQ. Celularity Inc. (NASDAQ: CELU) rose 36% to $0.5191. Celularity said it sees FY24 net sales of $50 million to $56 million. Cimpress plc (NASDAQ: CMPR) jumped 28.8% to $96.90 after the company reported better-than-expected second-quarter financial results and said the board authorized the repurchase of up to $150 million of company shares. TuSimple Holdings Inc. (NASDAQ: TSP) rose 28% to $0.2950. Elevai Labs, Inc. (NASDAQ: ELAB) gained 23.5% to $0.84 after gaining 8% on Wednesday. Asset Entities Inc. (NASDAQ: ASST) climbed 22.8% to $0.5650. Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares jumped 20.4% to $0.6649. Kiora Pharmaceuticals announced a private placement of up to $45 million. Evaxion Biotech A/S (NASDAQ: EVAX) gained 19.5% to $4.70. Evaxion Biotech announced pricing of $15 million public offering of 3.750 million ADS at $4.00 per ADS. Nextracker Inc. (NASDAQ: NXT) rose climbed 18.8% to $53.79 after the company reported better-than-expected third-quarter financial results. SunPower Corporation (NASDAQ: SPWR) jumped 18.1% to $3.5791. BioRestorative Therapies, Inc. (NASDAQ: BRTX) gained 16.4% to $1.8850. Corteva, Inc. (NYSE:
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. WD-40 reported quarterly earnings of $1.28 per share which exceeded the analyst consensus estimate of $1.05 per share. The company reported quarterly sales of $140.42 million, clocking in above the Street's estimate of $134.37 million. WD-40 shares jumped 17.3% to $277.56 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Nauticus Robotics, Inc. (NASDAQ: KITT) climbed 87.8% to $0.5501. Nauticus Robotics secured additional funding and appointed John W. Gibson, Jr as interim CEO. Clearmind Medicine Inc. (NASDAQ: CMND) shares jumped 47.7% to $3.0570. Clearmind Medicine completed a Type A Meeting with the FDA for clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of alcohol use disorder. Sana Biotechnology, Inc. (NASDAQ: SANA) gained 46.8% to $7.57. Sana Biotechnology recently announced FDA clearance of investigational new drug application for SC262. Ucommune International Ltd (NASDAQ: UK) jumped 37.8% to $4.98. Vicarious Surgical Inc. (NASDAQ: RBOT) rose 37% to $0.6851. Nvni Group Limited (NASDAQ: NVNI) climbed 35.2% to $2.6091. EchoStar Corporation (NASDAQ: SATS) gained 31% to $16.50. EchoStar completed merger with DISH Network Corporation. Amarin Corporation plc (NASDAQ: AMRN) climbed 28.8% to $1.25 after the company reported strong preliminary FY23 total revenues. Exicure, Inc. (NASDAQ: XCUR) shares rose 17% to $0.5501. Exicure was granted broad U.S. patent #11866700 for "Liposomal Nucleic Acid Constructs Presenting Antisense Oligonucleotides For Knockdown Of Interleukin ...
Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Ainos, Inc.(NASDAQ: AIMD) gained 142.6% to $4.20 in pre-market trading after falling more than 12% on Thursday. Safe and Green Development Corporation (NASDAQ: SGD) shares rose 34.5% to $1.83 in pre-market trading. Safe And Green Development recently issued an update on LOI for acquisition of Xene AI Software platform. Pinstripes Holdings Inc. (NYSE: PNST) shares gained 17.4% to $6.18 in pre-market trading after dipping over 35% on Thursday. Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) shares climbed 12.6% to $9.50 in pre-market trading. Fusion Pharmaceuticals said it has achieved alignment with the FDA on a protocol and development plan for FPI-2265. Inhibikase Therapeutics, Inc. (NASDAQ: IKT) shares gained 10.5% to $1.48 in pre-market trading. Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares rose ...
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) gained 73% to $0.4853. Intelligent Bio Solutions received National Association of Testing Authorities accreditation for its Intelligent Fingerprinting Drug Screening Solution. Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares surged 64% to $1.6601. Panbela Therapeutics shares jumped 120% on Monday after US WorldMeds received FDA approval of eflornithine. Jin Medical International Ltd.(NASDAQ: ZJYL) climbed 49.2% to $151.96 after jumping around 264% on Monday. ProSomnus, Inc. (NASDAQ: OSA) gained 27.6% to $0.8017. ProSomnus announced data published by Cureus Journal of Medical Science showed successful treatment of obstructive sleep apnea with prosomnus precision oral appliance devices. Infobird Co., Ltd (NASDAQ: IFBD) shares gained 27.4% to $1.7266 after the company inked a new business cooperation in software development of information technology system. MIND Technology, Inc. (NASDAQ: MIND) rose 23.1% to $5.86. Yoshiharu Global Co. (NASDAQ: YOSH) rose 21.1% to $6.20. Optex Systems Holdings, Inc (NASDAQ: OPXS) gained 18.2% to $4.86. Sunnova Energy International Inc. (NASDAQ: NOVA) jumped 16.3% to $15.32. Piper Sandler upgraded Sunnova Energy Intl from Neutral to Overweight and raised the price target from $13 to $26. Cipher Mining Inc. (NASDAQ: CIFR) rose 16% to $3.6450. LogicMark, Inc. (NASDAQ:
Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offering. Motus GI Holdings shares dipped 46.5% to $1.15 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Infobird Co., Ltd (NASDAQ: IFBD) shares rose 128.8% to $3.10 in pre-market trading after the company inked a new business cooperation in software development of information technology system. Jin Medical International Ltd.(NASDAQ: ZJYL) gained 76.7% to $179.96 in pre-market trading after jumping around 264% on Monday. SOBR Safe, Inc. (NASDAQ: SOBR) shares climbed 33.7% to $0.6250 in pre-market trading after declining around 7% on Monday. EG Acquisition Corp. (NYSE: EGGF) shares gained 33.2% to $14.38 in pre-market trading. Nxu, Inc. (NASDAQ: NXU) shares rose 31% to $0.0258 in pre-market trading. Nxu announced that Nasdaq approved company's request for continued listing, subject to Nxu demonstrating compliance with the listing rules on or before April 7, 2024. Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares surged 29.7% ...